MedTrace Logo

A Study of Modified Stem Cells in Stable Ischemic Stroke

NCT01287936 · Status: COMPLETED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 18

Last updated 2023-02-03

Study results available
· View outcomes & findings →

Summary

The primary purpose of the clinical study is to determine the safety of a modified stem cell SB623 when administered to chronic, stable ischemic stroke patients. A second purpose is to determine whether SB623 might improve stroke symptoms. Chronic, stable ischemic stroke patients must be between 6 and 60 months after their stroke, and with only this one prior stroke, and with no further improvement from physical therapy.

Conditions

  • Chronic Ischemic Stroke

Interventions

BIOLOGICAL

SB623

SB623, a modified stem-cell product

Sponsors & Collaborators

  • SanBio, Inc.

    lead INDUSTRY

Principal Investigators

  • Gary K Steinberg, M.D., Ph.D. · Stanford University

  • Lawrence R Wechsler, M.D. · University of Pittsburgh Medical Center

  • Joshua M Rosenow, M.D.,FACS · Northwestern University Feinberg School of Medicine

  • James Markert, M.D. · University of Alabama at Birmingham

  • Robert E Gross, M.D., Ph.D. · Emory University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-01-31
Primary Completion
2015-08-31
Completion
2015-08-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01287936 on ClinicalTrials.gov